Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 693-702

  Schaenman, Joanna M ^a   Shashidhar, Sumana ^a   Rhee, Chanu ^b   Wong, Jonathan ^a   Navato, Shelly ^a   Wong, Ruby M ^b   Ho, Dora Y ^a   Arai, Sally ^a   Johnston, Laura ^a   Brown, Janice M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antithymocyte globulin; Bone marrow transplantation; Cytomegalovirus; Immune reconstitution; Nonmyeloablative

Indexed keywords

THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; INFECTION CONTROL; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; RADIATION DOSE; RISK FACTOR; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIREMIA; VIRUS REACTIVATION;

ADULT; AGED; ANTIGENS, VIRAL; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 79954626445     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.010     Document Type: Article

References (24)

1. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
2. Lilleri D., Fornara C., Chiesa A., Caldera D., Alessandrino E.P., Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93:248-256.
3. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
4. Cwynarski K., Ainsworth J., Cobbold M., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97:1232-1240.
5. Lowsky R., Takahashi T., Liu P.L., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005, 353:1321-1331.
6. Kohrt H.E., Turnbull B.B., Heydari K., et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009, 114:1099-1109.
7. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002, 99:1978-1985.
8. Nakamae H., Kirby K.A., Sandmaier B.M., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:694-703.
9. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
10. Yanada M., Yamamoto K., Emi N., et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 32:801-807.
11. Schetelig J., Oswald O., Steuer N., et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003, 32:695-701.
12. Mohty M., Faucher C., Vey N., et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000, 26:251-255.
13. Mohty M., Jacot W., Faucher C., et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003, 17:2168-2177.
14. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
15. Park S.H., Choi S.M., Lee D.G., et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transplant Infect Dis 2009, 11:413-423.
16. Juliusson G., Theorin N., Karlsson K., Frodin U., Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006, 37:503-510.
17. Einsele H., Kapp M., Grigoleit G.U. CMV-specific T cell therapy. Blood Cells Mol Dis 2008, 40:71-75.
18. Foster A.E., Gottlieb D.J., Sartor M., Hertzberg M.S., Bradstock K.F. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:501-511.
19. Moins-Teisserenc H., Busson M., Scieux C., et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2008, 198:818-826.
20. Pass R.F., Stagno S., Britt W.J., Alford C.A. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J Infect Dis 1983, 148:953-961.
21. Tu W., Chen S., Sharp M., et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 2004, 172:3260-3267.
22. Hassan J., Dolley S., Hall W. Immunological response to cytomegalovirus in congenitally infected neonates. Clin Exp Immunol 2007, 147:465-471.
23. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
24. Limaye A.P., Kirby K.A., Rubenfeld G.D., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.